We think that InMed’s proprietary technology could put $6.6 Billion in play and make it one of the strongest biotech stocks in the market and that InMed is in the right place at the right time to create real value for investors in the Industry.
InMed's most recent announcement is a game changer for Cannabis Biotechs, will it be the same for investors?
The value drivers are here, in the race to develop cannabis drugs, cannabinoid extracts are of paramount importance.
InMed's announcement on the biosynthesis of a cannabinoid for use in the formulation of a cannabinoid drug is revolutionary.
InMed has patented important Biosynthesis IP.
InMed is a tiny company with a big idea - use biosynthesis to create the cannabinoids found in tiny amounts in naturally grown marijuana, and scale them for mass production.
Just look back the biotech started by two co-founders who were bought by Eli Lilly (NYSE: LLY) in a $48 billion takeover on the back of a biosynthesis discovery.
InMed has even gone so far as to biosynthesize a cannabinoid and used it in their own drug development activities for treatment of glaucoma.
Even Cannabis drug heavy weight GW Pharma (NASDAQ: GWPH) can't do that!
Just think about that. InMed doesn't have to grow and harvest vast quantities of marijuana at the cost of millions of dollars, and they are building the capacity to scale up for mass production.
InMed is pioneering research in cannabinoid biosynthesis, and are one of only a few companies that are attempting to produce the 90+ cannabinoids WITHOUT TOUCHING THE PLANT!
This is so important that they've filed a patent for their proprietary biosynthesis process:
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program
Yesterday's press release is even more exciting as it shows the effectiveness of their biosynthesis program and their delivery system.
InMed: A Text Book Lesson in how Biotechs Drive Share Value Through Innovation.
The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye.
While other companies in the space are attempting to biosynthesize cannabinoids, InMed has already successfully biosynthesized cannabinoids and used them in their own drug formulation process, positioining them as a leader in the potential $5 Billion glaucoma market.
InMed's ability to produce cannabinoids at a fraction of the cost, identify possible treatments for each compound, and potential for scaling to mass production should be music to investors ears.
Savvy investors know that when a stock has a head start on the market, patents on their property and the technology to deliver it's - it is worth deeper a look.